In the skin, we have previously shown that CD4+ T cells are important in the pathogenesis of DM because of their increased recruitment and extensive IFNβ and IL-31 production, both of which we have shown to be decreased in tissue after lenabasum treatment in a phase 2 clinical trial6,14. The gene discussed is CD4; the disease is dermatomyositis.